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Abstract: Erectile dysfunction (ED) is a prevalent condition that affects men and their 
partners. Signiﬁ  cant improvements in the sexual lives of these couples have been achieved with 
the introduction of phosphodiesterase 5 (PDE5) inhibitors. A PDE5 inhibitor is now widely 
recognized as the ﬁ  rst-line therapy for the majority of men with ED. Currently, three PDE5 
inhibitors – sildenaﬁ  l, tadalaﬁ  l and vardenaﬁ  l – are approved to be taken as needed in antici-
pation of sexual activity, but only one of these, tadalaﬁ  l, has been approved to be taken once 
daily. The primary aims of this review are to summarize the patients’ and partners’ viewpoints 
of ED management with PDE5 inhibitors, and to determine whether once-daily tadalaﬁ  l can 
contribute to improving some psychological aspects of ED (such as sexual self-conﬁ  dence, 
spontaneity and time concerns) compared with on-demand tadalaﬁ  l or other PDE5 inhibitors 
taken by patients with ED.
Keywords: erectile dysfunction, once-daily treatment, patient and partner perspectives, 
phosphodiesterase 5 (PDE5) inhibitor
Introduction
Male erectile dysfunction (ED) is a prevalent condition deﬁ  ned as the persistent 
inability to obtain and maintain an erection sufﬁ  cient to permit satisfactory sexual 
performance.1,2 ED is now recognized as a comorbid condition, especially in men with 
cardiovascular disease and diabetes mellitus.3 Moreover, ED also affects psychological 
health, eroding self-image, causing emotional distress, impairing marital relations and, 
therefore, compromising the quality of life of patients and their partners.4,5 Before the 
introduction of oral drugs, pharmacological ED treatment was limited to penile injec-
tions or intraurethral insertion of vasoactive agents or prostaglandin E1.
Use of a medication that inhibits phosphodiesterase type 5 (PDE5) is now widely 
recognized as the ﬁ  rst-line therapy for the majority of men with ED.6,7 Currently, three 
PDE5 inhibitors – sildenaﬁ  l, tadalaﬁ  l and vardenaﬁ  l – are approved to be taken as 
needed before anticipated sexual activity. Many factors can inﬂ  uence patient preference 
for an ED therapy: drug attributes (efﬁ  cacy, safety, tolerability and pharmacokinetic 
properties) as well as behavioral, psychological and relationship factors. Although 
PDE5 inhibitors are easy to use, men must ingest these oral agents on-demand before 
sexual activity, and thus remain temporally linked to treatment. For some patients and 
their partners, planning sexual activity around taking a drug is burdensome. Recent 
study results demonstrated that chronic administration, with tadalaﬁ  l8 dosed at 2.5, 5 
or 10 mg taken once daily, might offer another valuable option for ED treatment.9,10 
In 2007, 2.5 and 5 mg tadalaﬁ  l for once-daily use were approved by the European 
Commission for the treatment of ED, and became available in many states of the 
European Union. Based on patient choice and physician assessment, tadalaﬁ  l for 
once-a-day use is for patients who already respond to PDE5-inhibitor therapy and 
who anticipate sexual activity at least twice weekly. Once-daily tadalaﬁ  l represents Patient Preference and Adherence 2009:3 106
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a new therapeutic approach, able to provide some men with 
uninterrupted treatment for their ED. Therefore, it eliminates 
the need for planning sex within a limited timeframe and 
restores or develops freedom and choice of the moment for 
intercourse as a function of the couple’s expectations and/or 
desires. Using data from the scientiﬁ  c literature and clinical 
trials, we analyzed patients’ and partners’ viewpoints of ED 
management with PDE5 inhibitors, especially once-daily 
tadalaﬁ  l. This summary of our ﬁ  ndings suggests the inter-
est expressed in an additional therapeutic approach for this 
indication.
PDE5-inhibitor therapy and ED
As recommended in the guidelines written by the majority 
of scientiﬁ  c associations, the ﬁ  rst-line therapy for most men 
with ED is an oral PDE5 inhibitor. These medications are 
now widely considered safe and effective ED treatments, 
with reported efﬁ  cacy rates of 60% to 70%.2,6,11 Tadalaﬁ  l, 
one of the three PDE5 inhibitors currently on the market, is 
approved in more than 100 countries, including Australia, 
Brazil, Mexico, Canada, the United States and countries 
throughout Europe, as an oral treatment for ED. More than 
18 million patients worldwide have been treated with tadalaﬁ  l 
since its ﬁ  rst introduction in February 2003. Like the other 
PDE5 inhibitors, it was ﬁ  rst developed and approved for the 
treatment of ED on an as-needed basis, with a recommended 
starting dose of 10 mg in most patients that may be increased 
to 20 mg or decreased to 5 mg, based on individual efﬁ  cacy 
and tolerability. PDE5 inhibitors are available by prescrip-
tion only and are not for everyone. Men should discuss their 
medical conditions and all medications with their doctors to 
ensure that such a treatment is right for them and that they 
are healthy enough for sexual activity.
Until 2007, PDE5 inhibitors were taken on-demand by 
the majority of patients, being ingested prior to anticipated 
sexual activity. For the patient, in a way, taking an on-demand 
therapy assumes that he has a kind of appointment.
Indeed, on-demand PDE5-inhibitor use means making 
an appointment with oneself or one’s partner at a given time 
during the day or week. Optimization of its on-demand use 
means that the man identiﬁ  es the time best adapted to sat-
isfy his desire for sexual intercourse. Of course, he must be 
assured that his partner is of the same mind. So, the moment 
of sexual activity is determined by the couple and not the 
swallowing of the pill. Therefore, good usage of on-demand 
therapy requires the perfect harmony of the couple, associ-
ated with good lines of (non-verbal) communication, and pill 
intake before the onset of foreplay.
But some patients cannot foresee their desire for sexual 
intercourse in time for the tablet to be absorbed and become 
active. They want to have sex at the same time the desire 
strikes them.12 Thus, he should have taken the pill in 
advance, sometimes with no certainty of having intercourse. 
Because of its long half-life and 36 to 48 hours of clinical 
efﬁ  cacy, tadalaﬁ  l was preferred by these patients. Some 
couples, for example, became accustomed to taking tadalaﬁ  l 
Friday evening to prepare for the possibility of having inter-
course during the weekend. Other patients, and especially 
their partners, found their sexual desires to be inhibited by 
the idea of taking a pill. Their solution was to separate, as 
much as possible, the swallowing of the pill from the onset of 
sexual activity, so as to ‘forget’ ingesting the pill. Here again, 
because of on-demand tadalaﬁ  l’s particularly well-adapted 
pharmacokinetic properties, especially its 17.5-hour half-life 
assuring activity for about 2 days, patients often chose it.
It is certainly this advantage of prolonged activity that 
explains why preference studies conducted over the past 
several years found that signiﬁ  cantly higher numbers of 
patients, and their partners, preferred starting or pursuing 
tadalaﬁ  l rather than sildenaﬁ  l or vardenaﬁ  l.13–17
In a double-blind, crossover study, 215 men with ED were 
randomized to receive 4 weeks of treatment with tadalaﬁ  l 
20 mg or sildenaﬁ  l 50 mg, followed by the alternative treat-
ment after a 1- to 2-week drug washout, to take as needed 
up to once daily before sexual activity. In order to provide 
proper dosing instructions for each drug while maintaining 
investigators and/or patients blinding, two ‘nonexistent’ 
placebo arms were added in the protocol, stating that the 
patients could also be randomized to receive placebo with 
the tadalaﬁ  l or sildenaﬁ  l instruction set. However, it was not 
a true double-blind study as speciﬁ  c dosing instructions and 
statements concerning the onset and duration of action of the 
two PDE5 inhibitors may have introduced a source of bias. 
In this patient population, with a mean age of 49.8 years, 
chosen to mimic a new patient consulting his physician for 
treatment of ED, tadalaﬁ  l 20 mg was preferred to sildenaﬁ  l 
50 mg (66.3% vs 33.7%, respectively; p  0.001) for the 
initiation of ED therapy. The results of that study also showed 
that preference did not differ according to patients’ age, 
duration of ED, order in which treatments were received or 
previous sildenaﬁ  l exposure.13
Another study aimed to determine what percentage of 
ED patients currently taking sildenaﬁ  l would switch to 
tadalaﬁ  l. Among the 147 patients who were taking sildenaﬁ  l 
at stable ﬁ  xed doses of 25, 50 or 100 mg as needed and then 
received tadalaﬁ  l 20 mg, 133 (90.5%) preferred continuing Patient Preference and Adherence 2009:3 107
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oral therapy with tadalaﬁ  l and 14 (9.5%) with sildenaﬁ  l 
(p  0.001).14 To compare preference of sildenaﬁ  l or tadalaﬁ  l 
to treat ED in men naive to PDE5 inhibitors, 367 men with ED 
were randomized to receive sildenaﬁ  l for 12 weeks followed 
by tadalaﬁ  l for 12 weeks or vice versa. After treatment, 29% 
of men chose sildenaﬁ  l and 71% chose tadalaﬁ  l (p  0.001) 
for ED therapy during an 8-week extension.15
To compare sildenaﬁ  l, vardenaﬁ  l and tadalaﬁ  l, the three 
PDE5 inhibitors currently available, a prospective, ﬁ  xed-dose 
preference study was conducted, with a crossover design. All 
90 patients who completed this study were naive to all ED 
treatments, including PDE5 inhibitors. Drug preference was 
assessed by evaluating subjective elements that the patients 
had taken into account in making their choices: 25 (27.8%) 
opted to continue sildenaﬁ  l, 18 (20%) chose vardenaﬁ  l and 
47 (52.2%) preferred tadalaﬁ  l. Moreover, although the three 
medications markedly improved erectile function, statisti-
cally signiﬁ  cant differences in the International Index of 
Erectile Function (IIEF) score and responses to the Erectile 
Dysfunction Inventory of Treatment Satisfaction (EDITS) 
Questionnaire were found between tadalaﬁ  l and the two 
other drugs (p  0.0001), but not between sildenaﬁ  l and 
vardenaﬁ  l.16
All these studies examined several variables, like efﬁ  cacy, 
impact on quality of life and self-esteem from a male perspec-
tive. But women should also be involved in assessment and 
treatment decisions when ED is a problem for their partners, 
and recommendations have been made that research should 
focus on the impact of ED on women and the couple, rather 
than simply the man.18 In a recent prospective investigation, 
women were asked for the ﬁ  rst time which drug they pre-
ferred their partners to use when treated for ED, and why they 
preferred it.17 According to those ﬁ  ndings, a large majority 
of women chose tadalaﬁ  l over sildenaﬁ  l (79.2% and 15.6%, 
respectively; p  0.0001). The main reasons the women 
gave as inﬂ  uencing their treatment preference were more 
relaxed and natural experiences leading to more intimacy, 
enjoyment and increased sexual satisfaction, a longer lasting 
effect of tadalaﬁ  l, increased sexual frequency and the ﬂ  ex-
ibility offered by the drug in terms of time frames. As noted 
in that report, the female perspective, compared to that of 
men, reﬂ  ected the importance of factors above and beyond 
obtaining and maintaining an erection for sexual pleasure 
and enhancement of the couple’s relationship.
For the patients, the factors most signiﬁ  cantly associated 
with treatment preference were differences in time concerns, 
choice of dose, intercourse satisfaction, number of sexual 
attempts, satisfaction with erection hardness and the absence 
of or only minor side effects.19 Although preference studies 
have shown that all the PDE5 inhibitors were highly effective, 
the majority of patients seemed to prefer tadalaﬁ  l because 
it is easier to take, can be ingested at any time of the day, 
and its property of enabling them to achieve an erection, 
with sexual stimulation, long after taking the drug (eg, 8, 16 
or 24 hours later), leading to higher sexual self-conﬁ  dence 
and spontaneity and fewer time concerns related to sexual 
encounters.7,19
However, poor treatment satisfaction was reported by 
some men using on-demand PDE5 inhibitors. They want to 
be independent of scheduling their love life and to disconnect 
treatment from sexual intercourse, to enable them and their 
partners to be free to love and to retrieve a sexual life like 
before. For these men, the constant association of swallow-
ing a pill and sexual relations, inherent in using on-demand 
PDE5 inhibitors, could even be a source of psychological 
and behavioral distress.
As we indicated above, inquiries in large populations of 
men suffering from ED and treated with PDE5 inhibitors 
showed that some patients did not respond to on-demand 
therapies either because they found swallowing the pill just 
prior to having sex disturbing or they had difﬁ  culty identify-
ing when they would have such relations.12 Use of on-demand 
tadalaﬁ  l, although preferred by them, did not correspond 
completely to their expectations, because they still had to 
take a pill in connection with sexual activity. They wanted 
not to be systematically and continuously obliged to link pill 
taking with sexual activity.
These observations motivated the development of a new 
therapeutic approach for this indication, with more frequent 
or chronic dosing of a PDE5 inhibitor. Therefore, some sex-
ologists, andrologists and urologists devised a new dosing 
regimen, with tadalaﬁ  l taken 3 times per week, to determine 
whether this chronic PDE5-inhibitor dosing regimen might 
offer a valuable ED-treatment option.
Chronic-dosing regimen: the ﬁ  rst step
The Scheduled Use versus on-demand Regimen Evaluation 
(SURE) study was the ﬁ  rst comparative trial with an alterna-
tive dosing schedule.20,21 In 4262 men with ED, it investigated 
treatment efﬁ  cacy and patient preference for 20 mg tadalaﬁ  l 
taken on-demand (maximum one dose per day and before 
sexual activity) versus 3 times per week for 5 to 6 weeks. 
After a 1-week washout period, patients were crossed over 
to the alternate regimen for 5 to 6 weeks. At the end of on-
demand and 3 times per week treatment period, a normal 
EF domain score (26) was reported by 60.2% and 62.3% Patient Preference and Adherence 2009:3 108
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of patients. Both treatments were equally efﬁ  cacious and 
well-tolerated, but a substantial number of men preferred 
chronic dosing (42.2%) versus 57.8% for on-demand. More-
over, patients on the alternative dosing regimen (3 times per 
week) signiﬁ  cantly changed their sexual behavior and had 
sexual attempts distributed over a wide period of time post 
dosing, with 47% for on-demand and 71% for 3 times per 
week performed beyond the ﬁ  rst 4 hours post dosing, prefer-
ably in the evening and morning hours.22 As the aim of this 
study was not to demonstrate the superiority of the 3 times 
per week regimen compared to the on-demand regimen, the 
results showed that the two regimens provide another treat-
ment option by giving men with ED and their partners unique 
dosing ﬂ  exibility with tadalaﬁ  l. In a retrospective analysis 
of pooled data from clinical trials of tadalaﬁ  l using placebo-
controlled and open-label study designs, the frequency of 
serious cardiovascular treatment-emergent adverse events 
(CVTEAEs) was shown to be low in all groups evaluated.23 
In addition, the CVTEAE rate in tadalaﬁ  l-treated patients was 
independent of the dosing regimen, on-demand or 3 times 
per week, and comparable with that for placebo-treated 
patients, thereby demonstrating the safety of the chronic-
dosing regimen.
Despite the potential advantages of chronic dosing 
compared to on-demand regimens, taking a treatment 3 times 
per week seems not to be very easy and convenient for a 
majority of men with ED. They must note and remember 
on what days of the week the medication has to be taken. In 
response to these considerations, a new daily-dosing regimen 
was investigated, which also allowed a lower PDE5-inhibitor 
dose to be taken.
IPDE5 and daily dosing: a new 
treatment option
Tadalaﬁ  l differs in several ways from the other two PDE5 
inhibitors currently available. Its molecule belongs to a dis-
tinct chemical class characterized by a different structure. 
Because of its Tmax of 2 hours, tadalaﬁ  l starts to take effect 
16 to 60 minutes after intake. Its plasma half-life (T½) is 
17.5 hours, as opposed to 4 to 5 hours for sildenaﬁ  l and 
vardenaﬁ  l, which results in improved erectile function and 
the ability to obtain and maintain one or several erections 
over the 36 hours following intake.21,25 Indeed, clinical trials 
conducted with orally administered, on-demand tadalaﬁ  l for 
patients with ED demonstrated real life improved sexual 
activity with prolonged windows of opportunity for sexual 
activity. Furthermore, the rate and extent of tadalaﬁ  l absorp-
tion are not affected by food.24
To treat ED, tadalaﬁ  l should be taken no more than once 
daily (Cialis®, summary of product characteristics). Steady-
state plasma concentrations are reached after 5 days of 
once-daily intake and that regimen affords tadalaﬁ  l exposure 
1.6 times greater than after a single oral dose.26 A cumulative 
plasma exposure equivalent to on-demand doses of 16 mg 
and 8 mg could be obtained after 5 days of daily ingestion 
of 10 mg or 5 mg of tadalaﬁ  l.9 Therefore, tadalaﬁ  l phar-
macokinetic characteristics, particularly its long half-life 
(17.5 hours) and its sustained plasma concentrations after 
daily dosing, have made it one of the best candidates for 
once-daily dosing, which may be an attractive, alternative, 
oral treatment for patients with ED. Numerous clinical trials 
have shown the efﬁ  cacy, safety and tolerability of different 
tadalaﬁ  l doses taken once daily.
Two open-label studies compared the efﬁ  cacy and safety 
of once-daily versus on-demand tadalaﬁ  l.27,28 In the ﬁ  rst 
study, 112 men with moderate-to-severe ED previously 
unresponsive to on-demand tadalaﬁ  l were treated with 10 mg 
tadalaﬁ  l once daily.27 The 10 mg daily dose resulted in mean 
improvement of IIEF scores of 12.8 and 8.2 compared to 
pretreatment and on-demand baseline values, respectively 
(p  0.001), and 58% of intercourse attempts (as assessed 
with Sexual Encounter Proﬁ  le diary question 3 [SEP3]) were 
successfully completed (p  0.001). More patients reported 
improved erections with once-daily compared to on-demand 
tadalaﬁ  l (69% versus 42%, respectively), demonstrating an 
effective salvage strategy for previous non-responders. The 
second study evaluated the efﬁ  cacy, safety and tolerability 
of on-demand 20 mg versus once-daily 10 mg tadalaﬁ  l in 
145 men with mild to severe ED of various etiologies.28 
Once-daily tadalaﬁ  l was associated with a better efﬁ  cacy 
proﬁ  le compared with on-demand tadalaﬁ  l. All the patients 
experienced signiﬁ  cant improvement in the IIEF-erectile 
function (EF) domain, but with mean once-daily dose 
changes signiﬁ  cantly higher than for on-demand tadalaﬁ  l 
(p  0.05). Moreover, patients taking once-daily tadalaﬁ  l 
successfully completed sexual intercourse significantly 
more frequently than the patients taking tadalaﬁ  l on-demand 
(p  0.05). In that study, 72% of the patients expressed a 
preference for once-daily dosing. Based on the results of 
those two open-label studies, the authors concluded that the 
efﬁ  cacy of once-daily tadalaﬁ  l appeared to be better than 
that of on-demand use.
An initial 12-week, randomized, double-blind and 
parallel-group study was conducted on 268 men with ED.9 
The primary outcome end points were changes of IIEF-EF, 
Sexual Encounter Proﬁ  le (SEP) question 2 (SEP2; “Where you Patient Preference and Adherence 2009:3 109
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able to insert your penis into partner’s vagina?”) and SEP3 
(“Did your erection last long enough for you to have suc-
cessful intercourse?”) questions. Treatment tolerability and 
safety were also assessed. For patients treated with placebo 
or once-daily 5 mg or 10 mg tadalaﬁ  l, respective score modi-
ﬁ  cations from baseline to end point were: 0.9%, 9.7% and 
9.4% for the IIEF-EF; 11.2%, 36.5% and 39.4% for SEP2; 
and of 13.2%, 45.5% and 50.1% for SEP3. At the end of the 
study and for the respective treatment groups, 28.3%, 84.5% 
and 84.6% of the patients reported improved erections, and 
8.3%, 51.5% and 50.5% reported “no ED” (deﬁ  ned as IIEF 
26–30). All comparisons between tadalaﬁ  l (5 mg or 10 mg) 
and placebo were highly signiﬁ  cant (p  0.001). The results 
also showed that once-daily 5-mg or 10-mg tadalaﬁ  l was 
well tolerated. Adverse events described by at least 5% of 
the patients were: dyspepsia, headaches, back pain, upper 
abdominal pain and myalgias. Only nine (3.4%) patients 
discontinued therapy because of adverse events.
More recently, the efﬁ  cacy and safety of lower tadalaﬁ  l 
doses taken once daily to treat ED was assessed in a 
randomized, double-blind, placebo-controlled, parallel-
design study in the US.10 Responses to once-daily 2.5 mg 
or 5 mg tadalaﬁ  l were compared to placebo, for 24 weeks. 
The primary efﬁ  cacy endpoints were change from baseline 
to 24 weeks in mean IIEF-EF domain score, SEP2 and 
SEP3. Changes in the Psychological And Interpersonal 
Relationship Scales (PAIRS) were included in the secondary 
efﬁ  cacy endpoints. Efﬁ  cacy results indicated signiﬁ  cantly 
improved erectile function with tadalaﬁ  l versus placebo 
for all three primary study end points. At 24 weeks, more 
signiﬁ  cant mean changes from the baseline IIEF-EF scores 
were observed for the 2.5 mg (6.1) and 5 mg tadalaﬁ  l (7.0) 
groups compared to the placebo group (1.2) (p  0.001); 
with respective baseline-to-end-point changes of 24.3%, 
26.2% and 5.2% for SEP2; and 31.2%, 35.1% and 9.5% for 
SEP3 (p  0.001). The efﬁ  cacy results were similar across 
the 24-week observation period, suggesting no treatment 
resistance. The efﬁ  cacy of the 5 mg tadalaﬁ  l dose was better 
than that of 2.5 mg tadalaﬁ  l. This apparent dose  -response 
was observed for IIEF-EF domain scores and responses 
to SEP2 and SEP3 for patients with mild, moderate or 
severe ED. At 24 weeks, treatment with tadalaﬁ  l 2.5 and 5 mg 
improved PAIRS Sexual Self-conﬁ  dence Domain scores 
when compared with placebo (both p  0.001), but with no 
signiﬁ  cant differences in the PAIRS Spontaneity Domain 
scores. Both once-daily tadalaﬁ  l doses were well tolerated, 
with low discontinuation rates because of adverse events and 
a low treatment emergent CVTEAE rate.
Based on the review and evaluation of data from these 
phase III, randomized, double-blind, placebo-controlled 
studies, the European Commission approved 2.5 mg and 
5 mg tadalaﬁ  l for once-daily treatment of ED in June 2007. 
Seven months later, in January 2008, the US Food and Drug 
Administration approved them. Data from all the clinical 
trials conﬁ  rmed that men with ED taking 2.5 mg or 5 mg 
tadalaﬁ  l once daily experienced improved erectile function 
compared with those taking a placebo. When taken without 
restrictions on the timing of sexual activity, once-daily 
tadalaﬁ  l was able to improve erectile function over the course 
of therapy. Moreover, a recent publication reporting on two 
open-label extension studies showed that once-daily 5 mg 
tadalaﬁ  l for up to 2 years was effective, making it a valid 
alternative to on-demand tadalaﬁ  l for men with ED.29
Therefore, when tadalaﬁ  l is taken daily, men can attempt 
sexual activity at any time. As part of a daily regimen, 
tadalaﬁ  l may be taken at 2.5 mg or increased to 5 mg, based 
on individual efﬁ  cacy and tolerability. This low-dose, once-
daily tadalaﬁ  l treatment option may be most appropriate for 
men with ED who anticipate more frequent sexual activity 
(eg, twice weekly). Furthermore, the couples who like to 
have choices or want to go back to a certain freedom in their 
sexual lives will appreciate the availability of a PDE5 inhibi-
tor for once-daily use. For the other men and their partners, 
treatment with on-demand tadalaﬁ  l taken will remain an 
appropriate regimen.
Adverse events reported by the patients taking on-demand 
tadalaﬁ  l were mainly headaches, upset stomach, nasal con-
gestion, backache, muscle aches, dizziness and ﬂ  ushing. In 
clinical trials of once-daily tadalaﬁ  l, the most commonly 
reported adverse events were headaches, indigestion, back 
pain, muscle aches, nasal congestion, ﬂ  ushing and limb pain. 
Most adverse events reported for on-demand or once-daily 
tadalaﬁ  l were transient and generally mild or moderate.9,10 
Just as on-demand tadalaﬁ  l has been shown to be safe and 
well tolerated when taken for up to 2 years,30 two dosing 
studies of long-term, open-label, once-daily tadaﬁ  l provided 
evidence that 5 mg tadalaﬁ  l was also well tolerated for up to 
2 years in men with ED.29
As for the other PDE5 inhibitors, tadalaﬁ  l is contraindi-
cated for patients taking nitrates, those with cardiac disease 
for whom sexual activity is not recommended, and those 
with non-arteritic anterior ischemic optic neuropathy. Once-
daily tadalaﬁ  l assures continuous plasma levels, which 
should be considered when evaluating the potential for 
interactions with certain medications (eg, nitrates, alpha-
blockers, anti-hypertensives and potent CYP3A4 inhibitors) Patient Preference and Adherence 2009:3 110
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and with substantial amounts of alcohol. PDE5 inhibitors 
were previously shown to cause no changes in seminal 
parameters.31 A multicenter, randomized, double-blind, 
placebo-controlled study demonstrated that once-daily 20 mg 
tadalaﬁ  l for 9 months (approximately three human sper-
matogenesis cycles) had no major adverse effects on sperm 
production or reproductive hormones in healthy men (or those 
with mild ED) at least 45 years old.32 More interestingly, 
PDE5-inhibitor use by men without ED may lead to a marked 
reduction of the post-ejaculatory refractory time, indicating 
that, in normal subjects, PDE5-inhibitor intake may have a 
positive inﬂ  uence on retumescence following ejaculation in 
the presence of a continuous erotic stimulation.31,33–35
Since once-daily tadalaﬁ  l (2.5, 5 or 10 mg) was proven 
effective and well tolerated in the general ED population, a 
recent study was undertaken to determine the efﬁ  cacy and 
tolerability of once-daily 2.5 mg or 5 mg tadalaﬁ  l by men 
with ED and diabetes.32 This randomized, double-blind, 
placebo-controlled, multicenter, 12-week study enrolled 298 
men with diabetes and ED. Patients who took either tadalaﬁ  l 
dose had clinically and signiﬁ  cantly improved IIEF-EF and 
mean success rates for vaginal penetration, completion of 
intercourse, and overall treatment satisfaction (p  0.005 
vs placebo). These results suggest that once-daily 2.5 mg 
or 5 mg tadalaﬁ  l may be a good alternative to on-demand 
therapy for some men with diabetes and ED, eliminating the 
need to plan sex within a limited time frame.
Conclusion
The primary purpose of this review was to summarize 
patient and partner viewpoints on ED management with 
PDE5 inhibitors, and help determine whether once-daily 
tadalaﬁ  l can improve some psychological aspects (such 
as sexual self-conﬁ  dence, spontaneity and time concerns) 
compared to on-demand tadalaﬁ  l or other PDE5 inhibitors 
in these patients.
When approved in 2003, on-demand 10 mg or 20 mg 
tadalaﬁ  l was the ﬁ  rst and only PDE5 inhibitor clinically 
proven to provide sustained efﬁ  cacy for up to 36 hours. It 
transformed the oral treatment of ED by giving men the ability 
to achieve an erection long after taking the drug. Once-daily 
2.5 mg or 5 mg tadalaﬁ  l provides a new therapeutic alterna-
tive for men, who may be looking for a dosing option that 
avoids scheduling sexual activity, and for couples, who may 
prefer more convenience and spontaneity in their sexual lives. 
Taking once daily tadalaﬁ  l at a lower dose may be as effective 
as taking higher on-demand doses, and appears to be safe. 
In agreement with their physicians, patients now have the 
freedom to choose the dosing regimen most appropriate for 
them. Some may prefer the up to 36 hours of efﬁ  cacy provided 
by on-demand tadalaﬁ  l while others may want the unique 
beneﬁ  t provided by the new once-daily dosing option.
Disclosure
Dr. Gehchan is employee of Eli Lilly and Company
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